Therefore, based on the understanding of the mechanisms responsible for the G2 block and its importance in governing cell survival in response to DNA damage, there has been a substantial interest in the development of small molecule inhibitors of the G2 checkpoint for the sensitization of tumor cells to DNA-damaging cancer therapeutics including radiation—especially for tumor cells harboring defective p53 function [16, 17]. The gene discussed is TP53; the disease is cancer.